Promising combo for stubborn colon cancer never got off the ground
NCT ID NCT06603818
First seen Feb 20, 2026 · Last updated Apr 28, 2026 · Updated 14 times
Summary
This study aimed to see if combining two immunotherapy drugs (tiragolumab and atezolizumab) with targeted radiation could help people with a hard-to-treat type of metastatic colorectal cancer called microsatellite stable (MSS). The trial was designed for adults aged 18 and older with MSS mCRC who had at least two tumors. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.